Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Delayed Quote USD

Foghorn Therapeutics Inc. (FHTX)

Compare
3.3750
-0.2750
(-7.53%)
At close: April 1 at 4:00:01 PM EDT
3.5000
+0.12
+(3.70%)
After hours: April 1 at 6:06:32 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
22,602
22,602
34,155
19,228
1,319
Operating Expense
122,887
122,887
142,061
136,365
102,053
Operating Income
-100,285
-100,285
-107,906
-117,137
-100,734
Net Non Operating Interest Income Expense
11,900
11,900
10,875
5,675
-1,847
Other Income Expense
1,765
1,765
2,831
2,580
1,261
Pretax Income
-86,620
-86,620
-94,200
-108,882
-101,320
Tax Provision
--
--
4,226
--
--
Net Income Common Stockholders
-86,620
-86,620
-98,426
-108,882
-101,320
Diluted NI Available to Com Stockholders
-86,620
-86,620
-98,426
-108,882
-101,320
Basic EPS
-1.58
--
-2.34
-2.62
-2.73
Diluted EPS
-1.58
--
-2.34
-2.62
-2.73
Basic Average Shares
54,899.4320
--
41,974.4840
41,591.4330
37,171.1470
Diluted Average Shares
54,899.4320
--
41,974.4840
41,591.4330
37,171.1470
Total Operating Income as Reported
-102,683
-102,683
-107,906
-117,137
-100,734
Total Expenses
122,887
122,887
142,061
136,365
102,053
Net Income from Continuing & Discontinued Operation
-86,620
-86,620
-98,426
-108,882
-101,320
Normalized Income
-84,222
-84,222
-98,426
-108,882
-100,087
Interest Income
11,900
11,900
10,875
5,675
59
Interest Expense
--
--
--
--
1,906
Net Interest Income
11,900
11,900
10,875
5,675
-1,847
EBIT
-100,285
-100,285
-107,906
-117,137
-99,414
EBITDA
-97,165
-97,165
-104,455
-113,816
-96,187
Reconciled Depreciation
3,120
3,120
3,451
3,321
3,227
Net Income from Continuing Operation Net Minority Interest
-86,620
-86,620
-98,426
-108,882
-101,320
Total Unusual Items Excluding Goodwill
-2,398
-2,398
--
--
-1,233
Total Unusual Items
-2,398
-2,398
--
--
-1,233
Normalized EBITDA
-94,767
-94,767
-104,455
-113,816
-94,954
Tax Rate for Calcs
--
--
0.0002
--
--
12/31/2021 - 10/23/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SLDB Solid Biosciences Inc.
3.4450
-6.89%
 
PRLD Prelude Therapeutics Incorporated
0.7703
+0.30%
 
KYMR Kymera Therapeutics, Inc.
25.24
-7.80%
 
NRIX Nurix Therapeutics, Inc.
10.47
-11.87%
 
MOLN Molecular Partners AG
3.8400
-5.65%
 
ITOS iTeos Therapeutics, Inc.
5.63
-5.70%
 
TNGX Tango Therapeutics, Inc.
1.2800
-6.57%
 
CCCC C4 Therapeutics, Inc.
1.4350
-10.31%
 
NUVL Nuvalent, Inc.
68.00
-4.12%
 
CGEM Cullinan Therapeutics, Inc.
7.50
-0.92%